Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has granted approval to a new single capsule formulation of Reyataz, manufactured by Bristol-Myers Squibb, for the treatment of HIV-1 infection in adults as part of combination therapy.
Subscribe to our email newsletter
Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the Reyataz 300mg single capsule formulation can replace two Reyataz 150mg capsules. The treatment is indicated for patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate and patients who have never taken anti-HIV medicines that require Sustiva as part of their anti-HIV drug regimen.
“With the Reyataz 300mg single capsule formulation approval, Bristol-Myers Squibb now has one pill, once-daily HIV medicine options available in three drug classes, as part of combination therapy,” said Anthony Hooper, president, US Pharmaceuticals, Bristol-Myers Squibb.
Reyataz is an anti-HIV drug that blocks the action of the HIV protease enzyme, which is needed for the virus to multiply. Reyataz has been studied in 48-week trials in both patients who have taken or have never taken anti-HIV medicines.